Evidence map›Paper›PMID 39125971›Full record

ArticleInternational journal of molecular sciences2024

The Vasopressin Receptor Antagonist Tolvaptan Counteracts Tumor Growth in a Murine Xenograft Model of Small Cell Lung Cancer.

Laura Naldi, Benedetta Fibbi, Simone Polvani, Chiara Cirillo, Francesca Pasella, Francesca Bartolini, Francesca Romano, Alessandra Fanelli, Alessandro Peri, Giada Marroncini

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Laura NaldiPituitary Diseases and Sodium Alterations Unit, AOU Careggi, 50139 Florence, Italy.
Benedetta FibbiPituitary Diseases and Sodium Alterations Unit, AOU Careggi, 50139 Florence, Italy.
Simone PolvaniGastroenterology Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50139 Florence, Italy.
Chiara CirilloEndocrinology, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, AOU Careggi, 50139 Florence, Italy.
Francesca PasellaEndocrinology, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, AOU Careggi, 50139 Florence, Italy.
Francesca BartoliniEndocrinology, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, AOU Careggi, 50139 Florence, Italy.
Francesca RomanoCentral Laboratory, Careggi University Hospital, 50139 Florence, Italy.
Alessandra FanelliCentral Laboratory, Careggi University Hospital, 50139 Florence, Italy.
Alessandro PeriPituitary Diseases and Sodium Alterations Unit, AOU Careggi, 50139 Florence, Italy.ORCID 0000-0001-6417-434X
Giada MarronciniPituitary Diseases and Sodium Alterations Unit, AOU Careggi, 50139 Florence, Italy.ORCID 0000-0002-6611-8103

Funding

PRIN 2017R5ZE2C
6 · The paper itself

Abstract

We have previously demonstrated that the vasopressin type 2 receptor (AVPR2) antagonist tolvaptan reduces cell proliferation and invasion and triggers apoptosis in different human cancer cell lines. To study this effect in vivo, a xenograft model of small cell lung cancer was developed in Fox1

Indexed as

Antidiuretic Hormone Receptor AntagonistsCell ProliferationLung NeoplasmsMice, NudeReceptors, VasopressinSmall Cell Lung CarcinomaTolvaptanXenograft Model Antitumor AssaysAnimalsApoptosisCell Line, TumorHumansMiceSignal TransductionAntidiuretic Hormone Receptor AntagonistsReceptors, VasopressinTolvaptanhyponatremiasmall cell lung cancertolvaptanvasopressin receptor

Identifiers

PMID39125971
PMCPMC11313280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.